Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

First Signs Of Efficacy From Biogen’s Tau-Targeting Antisense Drug

Oct 25 2023

• By Andrew McConaghie

Biogen

Related Content

Biogen/Ionis’ Tofersen Wins Accelerated Approval In ALS Subgroup – A Significant But Narrow Precedent

Apr 25 2023

Biogen Drug Sends Tau Into Reverse: An Alzheimer’s Breakthrough In The Making?

Apr 03 2023

Alnylam Buoyed By Early Alzheimer’s Gene Silencing Success

May 05 2023

Related Companies

Biogen, Inc.

Ionis Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Companies Research & Development Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window